Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm not sure of his "alleged" net worth, but he was paid 35 million for his rights in Zycam. The last PR indicated he was still working for IP on new products. It was apparent his contract with Itonis was amended.
Unfortunately , a stock feeds on news on the OTC. SIPC must execute its plans to substantiate a higher PPS. Then, with strong financials and a national brand, the company will be a "game changer". NDAI!
Waiting for another PR in the next two weeks on production and distribution news in Chicago area; the status of Major Hemp HIPA. The distribution of MHBA in CANS to Colorado customers. It's coming. Then Legalization of Hemp by 9/30/2018. Load SIPC at these PPS bargains while you can. $$$$$$$$ SIPC $$$$$$$$$$$$
According to the NDC Drug A-Z Index, the NDC for Itonis Plus is 59067-002
Proprietary Name: Emesyl Plus
Non-Proprietary Name: Natrum Sulphuricum, Kali Phosphoricum, et al.
Dosage Form: Spray
Route Name: Nasal
Company Name: Itonis
Product Type: Human OTC drug
59067-001 is the NDC for Emesyl (Nausea Relief Spray)
I have Itonis (ITNS) on TD Ameritrade and in an IRA. I have e-mailed Itonis several times with no response. Whether there is a "silent period" or NDC with distributors, I don't know.
I seem to remember the .40 to .50 PPS to even consider a RS and an "uplisting". However, as you mentioned, I would rather wait until the company's financials are strong and the PPS is much higher. I'm sure, based on his experience, Peter Smith would pick the right time to "uplist".
Myec's PPS is .001 and flirting with the "trips". Ihub pumpers on the board only stockholders buying. LOL!
I think you're correct about ARGQ's PPS for a RS. I've always felt that since Peter and Enzo visited the NYSE, which was displayed to the Ihub website, they aspired to upgrade to a major exchange some day.
A Reverse Split will hurt a company unless it is couple with an "uplisting" to a respectable, regulated exchange. Let ARGQ's PPS rise to a much higher level based on good earnings, growth and company exposure in the market.
I'm patiently waiting for the next PR/Update which should occur around the end of August. It should include MHIPA and Church Street production and distribution. NDAI!
SIPC is going ^^^ and away! $$$$$$$$$$$ S I P C $$$$$$$$$$$$$$$
If they execute their plans as stated, .06 to .08 PPS is highly possible.
With SIPC I have the greatest confidence and patience. GLTA!
Yes, it is a shame for the shareholders.
DUUO's been a huge disappointment and I had U.S. funds to acquire in mind when I posted. But they should concentrate on the nine funds they initially selected. GLTA!
It all depends on the Legalization of Hemp and execution of the Chicago production and distribution of MHIPA. NDAI!
Not today!
Prediction: With SIPC executing its plans in CO, IN and Il, the company's PPS will end 2018 between .04 and .06. NDAI!
So does every other shareholder. One goal I'd like to see would be an "upgrade" to a respectable, regulated exchange where ARGQ's PPS is much closer to "fair value". When a huge PR with a value driven catalyst is met with Buying volume and an increase in PPS. I also would encourage ARGQ to open a NYC office and acquire clients in the U.S.A. where business is conducted in a more timely manner and that time is money. Consideration should also be given to the "exchange" an IPO is issued on so that there is at least potentially a market for the stock.
Until ARGQ gets off the OTC and upgrades to NASDAQ or a higher exchange, ARGQ will never show "fair value" in the marketplace. Yes, I believe the company should be more transparent with meaningful catalyst driven PRs. Furthermore, Argentum should incorporate procedures to expedite business closings and realize revenue and or equity positions faster as to increase the life blood of operations: CASH FLOW!
That's life in the OTC!
I'll take today's PPS performance anytime, but could have been better except for last minute "painting". SIPC will make up for it tomorrow.
Thank you for that honest post regarding Myec's responsibility to attain banking. But the non-performance was in not tendering the app.
Maybe Ed knows why he/Myec did not perform on the contract. Itonis would have been using it in Southern California handling marijuana, gambling and retail payments from customers. Furthermore, Myec would have benefitted hugely from the e-transactions. This just one of the many acts of non-performance by Myec and probably would be one of the highlights in "audited financials", if they were available.
Ed/Myec failed for not honoring contracts; eg., the e-mobile apps to licensees like Itonis. If another stockholder dumps 5,000,000 shares, this stock will be in the trips too. LOL!
I'm not waiting on the .02 PPS principal, but on a closing of a larger fund or funds to move this stock. However, this company must operate with multiple Revenue streams: Management consulting fees, capital/management restructuring, personnel fees, clients funds secured with closing fees and IPOs resulting in Equity positions. Management boasted in the past that there were vast financing sources in the Middle East, Europe and Asia to accommodate their clients. However, the sources of funds never materialize which forced management to change its focus on financial advisory firms with funds under management. GLTA!
Hemporer not as good as Major Hemp HIPA! NDAI! MHBA and MHIPA both produced by the only hemp publicly traded company.
Major Hemp's IPA will be much better! NDAI!
Market for Emesyl is growing through availability at more venues. Emesyl Plus will definitely be a good addition for the product as hemp ingredient will induce easier, more comfortable application and health benefits of hemp. Company could possibly introduce a spray containing CBD in the near future. It is also possible the price of Emesyl was increased due to increased demand. GLTA!
Numbers change over time and so do percentages. Revenue in 2018 is the problem, not G&A; but that will improve shortly.
$$$$$$$$$$$$ ARGQ $$$$$$$$$$$$$
Based on what's in the pipeline with the Expansion of Products and Legalization of Hemp, investors and prospects should be buying SIPC frequently. I'm investing on a monthly basis and have a "profitable position". GLTA!
You don't understand my post or Argentum 47's status.
G&A is basically "fixed expenses". If the Revenue was anywhere near where it should be, the percentage of G&A to Revenue would be much lower. And yes, I find fault with the transparency of managements' communication too. There was a time ARGQ was adding a client per month and proudly introduced James Goldie and Kevin Wynn to the professional staff. Growth was in the air. What happened?
It was projected that ARGQ' goal was 1.5 Billion in funds, so the company has a long way to go. I don't care about G&A or the number of funds under management. My short-term and long-term goal concern is primarily PPS. A close second is uplisting out of this OTC cesspool. As always GLTA!
When investors and prospects see the growth of revenue and profits in the next 10-Q, more affluent investors will be attracted to ARGQ and the PPS will rise to its "true value". Several more funds will be acquired during the rest of 2018.
$$$$$$$$$$$ A R G Q $$$$$$$$$$$$$$
The next financial firm with funds under management on the Isle of Man should close very soon. That will give ARGQ ownership of total funds under management in an amount over ninety (90) million dollars. That translates to a monthly management fee of at least $75,000. The empire keeps growing!
I'm sure all Longs wish for the same goals. They should open an office in NYC as projected and ARGQ would be on its way toward accomplishing its objectives. NDAI!
Based on the loans of $5.5 million, ARGQ could buy anywhere between 5 and 10 financial firms with funds under management, depending on the cost. The company has been examining 9 by last report.
So would I. Say at $1.00+ PPS.
When you exercise DD on ARGQ, everything lucrative I forward looking, especially the acquisitions of financial firms with funds under management. While the company has closed a U.K. fund, investors want to see a "profit" before investing or adding more. The company suffered a loss of 3.7 million dollars for the year ended 12/31/2017. It had a loss of $630,000 shown as "loss from operations" for the six months ended 6/30/2018. However, the latter statement reported a gain from investments available for sale of $1,500,000. Thus, the final line showed a net profit of over $600,000. I don't think investors were impressed with that accounting procedure. I guess it's proper based on GAAP. However, I'm sure all investors and prospects are waiting for a NET PROFIT FROM OPERATIONS, a proof of concept. I believe it's coming based on the acquisition of the many funds in the future. GLTA! Hold ARGQ Long and Strong!